Updates

News

2026

RASolute 302 Phase 3 Results Published in NEJM

Daraxonrasib, an oral RAS(ON) multiselective inhibitor, doubled overall survival vs. chemotherapy in previously treated metastatic pancreatic cancer (13.2 vs. 6.6 months; HR 0.40). Led by Dr. Eileen M. O’Reilly, Dr. Wungki Park’s mentor at MSK, and the RASolute 302 Trial Investigators.

2026

Setidegrasib Phase 1 Results Published in NEJM

First-in-class KRAS G12D degrader shows promising antitumor activity in advanced PDAC and NSCLC.

2026

POLAR Trial Published in Nature Medicine

Phase 2 maintenance pembrolizumab + olaparib demonstrates durable benefit in HRD metastatic pancreatic cancer.

Open

We Are Recruiting

We are looking for passionate researchers — postdoctoral fellows and research staff — to join our mission. Reach out if you are interested in translational PDAC research.